Gemini Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2015-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
3
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (66.7%)Phase 1
1 (33.3%)A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration
Phase 2
Terminated
- Conditions
- Neovascular Age-related Macular DegenerationRetinal DegenerationMacular DegenerationRetinal Disease
- Interventions
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- Gemini Therapeutics, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT04684394
- Locations
- 🇺🇸
Gemini Clinical Trial Site 16, Phoenix, Arizona, United States
🇺🇸Gemini Clinical Trial Site 11, Campbell, California, United States
🇺🇸Gemini Clinical Trial Site 9, Encino, California, United States
A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration
Phase 2
Terminated
- Conditions
- Geographic AtrophyMacular DegenerationRetinal DegenerationDry Age-related Macular DegenerationRetinal Disease
- Interventions
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2022-09-23
- Lead Sponsor
- Gemini Therapeutics, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT04643886
- Locations
- 🇺🇸
Gemini Clinical Trial Site, Virginia Beach, Virginia, United States
First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry Age Related Macular Degeneration
Phase 1
Completed
- Conditions
- Retinal DegenerationDry Age-related Macular DegenerationMacular DegenerationGeographic AtrophyRetinal Disease
- First Posted Date
- 2020-01-29
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- Gemini Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04246866
- Locations
- 🇺🇸
Associated Retina Consultants, Phoenix, Arizona, United States
🇺🇸Retinal Consultants of Arizona, Phoenix, Arizona, United States
🇺🇸California Retina Consultants, Santa Maria, California, United States
News
No news found